Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!
Jul 01, 2020
Over the past few decades Cancer has emerged as a major public health concern worldwide. Cancer is the second leading cause of deaths that takes place worldwide. Every sixth death is due to cancer, and in 2018 was estimated to be responsible for 9.6 million deaths. Costing people quality of lives and eventually lea...
Read More...
Jun 05, 2020
Prostate Cancer Market Size is Expected to Increase with a CAGR of 8.1% in the 7MM for the study period of 2017-30 owing to rich Pipeline, Increasing Awareness and Better Treatment Options. A malignancy of prostate glands, Prostate Cancer, develops slowly and remains confined to prostate glands, however, can inv...
Read More...
Apr 21, 2020
The U.S. FDA has given its nod to Seattle Genetics for its Tukysa (tucatinib) for advanced unresectable or metastatic HER2-positive breast cancer Genetics Tukysa (tucatinib) is a tyrosine kinase inhibitor of the HER2 protein, administered orally in combination with chemotherapy agents trastuzumab and capec...
Read More...
Mar 12, 2020
The U.S. FDA has granted Janssen Pharmaceutical’s drug JNJ-6372, a Breakthrough Therapy designation for the treatment of metastatic non-small cell lung cancer (NSCLC) The drug has been recommended for its use in NSCLC patients with epidermal growth factor (EGFR) Exon 20 insertion mutations, categorized wit...
Read More...
Jan 13, 2020
Malignant pleural mesothelioma (MPM) is a malignancy of pleural layers within the lung cavity and inner sides of the ribs. Year of research has revealed asbestos exposure as the primary cause of the malignancy. The longer the asbestos exposure, more is the risk of a person developing mesothelioma. It...
Read More...
May 02, 2019
EISAI now solely responsible for lemborexant Eisai today announced that its U.S. subsidiary has bought out Purdue Pharma L.P.’s rights in the worldwide collaboration for the development and commercialization of lemborexant, an investigational sleep-wake regulation agent being studied for the treatment of multip...
Read More...
Dec 18, 2018
HER2 Vaccine Candidate Meet Phase 1b Study An Australian biotech company stated its Human Epidermal Growth Factor Receptor 2 (HER2) vaccine candidate, HER-Vaxx, successfully finished its phase 1b clinical trial and head to a phase 2 study. The first tranche of data from the 14-patient trial comes...
Read More...
Aug 21, 2018
Kalydeco, the first Cystic Fibrosis drug of Vertex, got approved for infants The Food and Drug Administration has cleared Kalydeco drug of Vertex Pharmaceuticals for infants aged 12 to under 24 months. The approved drug treats the underlying cause of cystic fibrosis in children of this age with at least one mutatio...
Read More...
Feb 22, 2018
Ionis pharmaceuticals recently licensed-out its antisense drug to AstraZeneca in deal total worth up to USD 330 million Ionis Pharmaceuticals has recently licensed-out an antisense drug to AstraZeneca, bagging a payment of USD 30 million as an upfront licensing fee. AstraZeneca will now be taking care of the develo...
Read More...
Aug 10, 2017
Loom of Patent Expiry leads Bristol-Myers Squibb to nix 58 marketing jobs Bristol-Myers Squibb will soon bid farewell to its exclusive lock on a pair of HIV drugs—and, as a result, 58 workers will bid farewell to their jobs. The company is making changes to their HIV portfolio businessin anticipation of end-of-year ...
Read More...
Roche’s HER2-Positive Breast Cancer Treatment Franchise
Aug 13, 2024
Transforming Multiple Myeloma Treatment: The Promise of Novel Drug Classes
Jul 24, 2024
Newsletter/Whitepaper